BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kayesh MEH, Kohara M, Tsukiyama-Kohara K. An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants. Viruses 2021;13:2302. [PMID: 34835108 DOI: 10.3390/v13112302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Mcmanus D, Davis M, Ortiz A, Britto C, Dela Cruz CS, Topal J. Immunomodulatory agents for COVID-19 pneumonia. Clinics in Chest Medicine 2022. [DOI: 10.1016/j.ccm.2022.11.009] [Reference Citation Analysis]
2 Jiang Y, Zhao T, Zhou X, Xiang Y, Gutierrez‐castrellon P, Ma X. Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions. MedComm 2022;3. [DOI: 10.1002/mco2.154] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Pitaloka DAE, Izzati A, Amirah S, Syakuran LA. Multi Epitope-Based Vaccine Design for Protection Against Mycobacterium tuberculosis and SARS-CoV-2 Coinfection. AABC 2022;Volume 15:43-57. [DOI: 10.2147/aabc.s366431] [Reference Citation Analysis]
4 Zeng Q, Wang R, Hua Y, Wu H, Chen X, Xiao Y, Ao Q, Zhu X, Zhang X. Hydroxyapatite nanoparticles drive the potency of Toll-like receptor 9 agonist for amplified innate and adaptive immune response. Nano Res . [DOI: 10.1007/s12274-022-4683-x] [Reference Citation Analysis]
5 Dai J, Wang Y, Wang H, Gao Z, Wang Y, Fang M, Shi S, Zhang P, Wang H, Su Y, Yang M. Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients With Coronavirus Disease 2019. Front Microbiol 2022;13:948770. [DOI: 10.3389/fmicb.2022.948770] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kayesh MEH, Kohara M, Tsukiyama-Kohara K. Toll-like Receptor Response to Hepatitis C Virus Infection: A Recent Overview. Int J Mol Sci 2022;23:5475. [PMID: 35628287 DOI: 10.3390/ijms23105475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Marino A, Munafò A, Augello E, Bellanca CM, Bonomo C, Ceccarelli M, Musso N, Cantarella G, Cacopardo B, Bernardini R. Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations. Infectious Disease Reports 2022;14:360-71. [DOI: 10.3390/idr14030040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol 2022. [PMID: 35354968 DOI: 10.1038/s41579-022-00713-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 42] [Article Influence: 33.0] [Reference Citation Analysis]